This channel includes news on cardiovascular care delivery, including how patients are diagnosed and treated, cardiac care guidelines, policies or legislation impacting patient care, device recalls that may impact patient care, and cardiology practice management.
The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.
For artificial intelligence to truly transform care, the healthcare industry must address certain challenges. Jens Eldrup-Jorgensen, MD, a veteran vascular surgeon and member of the Society for Vascular Surgery, explains in a guest editorial.
The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks.
Regardless of effectiveness or lack thereof, pandemic-response measures like masking and social distancing give many people a sense of being better off with them than without them.
Generative AI of the “large language” kind has been an attention hog over the past 10 or 11 months. The buzz has been so loud and constant that it’s all but asking to be dismissed as hype.
Do you know who owns your personal favorite doctor’s practice? Could it be a healthcare conglomerate? An insurance company? A private equity firm? Amazon?
It’s easy to see the appeal of cross-market hospital mergers to the marrying partners. How these long-distance entwinements help patients is a separate question.
The new ranking, based on extensive survey data gathered by Newsweek, includes a total of 150 hospitals. Seven of the top 10 are located in the United States.
The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.
The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks.
Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.
